SEARCH SITE
VIRGINIA LAW PORTAL
- Code of Virginia
- Virginia Administrative Code
- Constitution of Virginia
- Charters
- Authorities
- Compacts
- Uncodified Acts
- RIS Users (account required)
SEARCHABLE DATABASES
- Bills & Resolutions
session legislation - Bill Summaries
session summaries - Reports to the General Assembly
House and Senate documents - Legislative Liaisons
State agency contacts
ACROSS SESSIONS
- Subject Index: Since 1995
- Bills & Resolutions: Since 1994
- Summaries: Since 1994
Developed and maintained by the Division of Legislative Automated Systems.
2018 SESSION
18105849DWHEREAS, idiopathic pulmonary fibrosis is a debilitating and generally fatal disease marked by progressive scarring of the lungs, causing an irreversible loss of the lung tissue's ability to transport oxygen; and
WHEREAS, idiopathic pulmonary fibrosis is the most common form of interstitial lung disease; the disease progresses quickly, often causing disability or death within three to five years; and
WHEREAS, there is no proven cause of idiopathic pulmonary fibrosis, and it is often misdiagnosed or underdiagnosed; and
WHEREAS, idiopathic pulmonary fibrosis is five times more common than cystic fibrosis and Lou Gehrig's disease, but the disease remains virtually unknown and receives a fraction of the research funding; and
WHEREAS, more than 132,000 United States citizens have idiopathic pulmonary fibrosis and more than 50,000 new cases are diagnosed each year; and
WHEREAS, approximately 40,000 people die each year due to idiopathic pulmonary fibrosis, which is as many as those who die each year of breast cancer in the United States; and
WHEREAS, between 3,000 and 4,000 Virginians suffer from idiopathic pulmonary fibrosis; and
WHEREAS, the Commonwealth has become a leader in research and treatment of idiopathic pulmonary fibrosis, with hundreds of lung transplants performed in Virginia hospitals over the last 10 years; and
WHEREAS, there is a critical need to increase research, awareness, and early detection of idiopathic pulmonary fibrosis, and ensure that treatment options for the disease are readily available for those who need them; now, therefore, be it
RESOLVED by the House of Delegates, the Senate concurring, That the General Assembly hereby commend idiopathic pulmonary fibrosis researchers and clinicians in Virginia; and, be it
RESOLVED FURTHER, That the Clerk of the House of Delegates prepare a copy of this resolution for presentation to the Virginia Board of Health as an expression of the General Assembly’s admiration for the vital contributions of idiopathic pulmonary fibrosis researchers and clinicians to the health and wellness of thousands of Virginians.